Palatin Technologies, Inc. (PTN)

1,7300 +0,0100 (+0,58%) Ab 10:46AM EDT. Markt geöffnet.

Palatin Technologies, Inc.

Cedar Brook Corporate Center
4-B Cedar Brook Drive
Cranbury, NJ 08512
United States
609 495 2200
https://palatin.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 34

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Carl Spana Ph.D.	Co-Founder, President, CEO & Director	979k	N/A	1962
Burns McClellan	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Stephen A. Slusher Esq.	Chief Legal Officer	N/A	N/A	N/A
Dr. Michael B. Raizman M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. James E. Hattersley	Senior Vice President of Business Development	N/A	N/A	1960
Mr. John Dodd Ph.D.	Senior Vice President of Preclinical Development	N/A	N/A	N/A
Mr. Robert Jordan	Senior Vice President of Program Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

Corporate Governance

Palatin Technologies, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.